Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43(10):757-70. 25. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent post-transplant lympho- proliferative disorder. Clin Microbiol Rev. 2010;23(2):350-66. 26. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein- Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis.2007;39(3): 235-44. 27. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lympho- proliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high risk patients. Curr Opin Hematol. 2008;15(6):576-85. 28. Kalinova L, Indrakova J, Bachleda P. Post-transplant lympho- proliferative disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153(4):251-7. 29. Kerkar N, Morotti RA, Madan RP, Shneider B, Herold BC, Dugan C, et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant. 2010;14(4):504-11. 30. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113 (20):4992-5001. 31. Omar H, Hagglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11(5):393-9. 32. Imashuku S, Teramura T, Konishi K, Kikuchi A, Tamura S, Maeda Y, et al. Treatment of Epstein-Barr vírus-associated peripheral T- cell lymphoma. Br J Dermatol. 2004;150(5):1038-40. Comment on: Br J Dermatol. 2002;147(6):1244-8. 33. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs. 2005;7(1):55-65. 34. Masjosthusmann K, Ehlert K, Eing BR, Roth J, Koehler G, Juergens H, et al. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;43(9):679-84. 35. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):471-82. 36. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4(2):222-30. Comment in: Am J Transplant. 2004;4(2):153-4. 37. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114(19):4002-8. 38. Baldanti F, Gatti M, Furione M, Paolucci S, Tinelli C, Comoli P, et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA- haploidentical stem cell transplantation. J Clin Microbiol. 2008; 46(11):3672-7. Rev Bras Hematol Hemoter. 2011;33(5):383-8 39. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus negative post-transplant lympho- proliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24(3):375-85. 40. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica. 2002;87(1):67-77. 41. Wolf H, zur Hausen H, Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol. 1973;244(138): 245-7. 42. Shah KM, Young LS. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Clin Microbiol Infect. 2009;15 (11):982-8. 43. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol. 2005;43(7):3066-73. 44. Desgranges C, deThe G, Wolf H, zur Hausen H. Further studies on the detection of the Epstein-Barr virus DNA in nasopharyngeal carcinoma biopsies from different parts of the world. IARC Sci Publ. 1975(11 Pt 2):191-3. 45. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37(1):132-6. 46. Leung E, Shenton BK, Jackson G, Gould FK, Yap C, Talbot D. Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. J Immunol Methods. 2002;270(2):259-67. 47. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG. American Society of Transplantation Infectious Diseases Community of Practice. Interlaboratory comparison of Epstein- Barr virus viral load assays. Am J Transplant. 2009;9(2):269-79. 48. Ljungman P. Molecular monitoring of viral infections after hematopoietic stem cell transplantation. Int J Hematol. 2010;91 (4):596-601. 49. Hakim H, Gibson C, Pan J, Srivastava K, Gu Z, Bankowski MJ, et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol. 2007;45(7):2151-5. 50. Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. Measurement of Epstein-Barr vírus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol. 2003;41(11):5245-9. 51. Hayden RT, Hokanson KM, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Valsamakis A, Balfour HH Jr; U.S. EBV Working Group. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol. 2008;46(1):157-63. 52. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Ruutu T, Mattila PS, et al. Lymphoproliferative disease after allogeneic stem cell transplantation pre-emptive diagnosis by quantification of Epstein- Barr virus DNA in serum. J Clin Virol. 2003;28(3):275-83. 53. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus- associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37(6):539-46. 54. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, et al. Patients at risk for development of post-transplant lympho- proliferative disorder: plasma versus peripheral blood mononuclear 387